Browse PTPRQ

Summary
SymbolPTPRQ
Nameprotein tyrosine phosphatase, receptor type, Q
Aliases DFNB84; deafness, autosomal recessive 84; DFNB84A; PTPGMC1; R-PTP-Q; phosphotidylinositol phosphatase PTPRQ; ......
Chromosomal Location12q21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Membrane Single-pass type I membrane protein
Domain PF00041 Fibronectin type III domain
PF00102 Protein-tyrosine phosphatase
Function

Phosphatidylinositol phosphatase required for auditory function. May act by regulating the level of phosphatidylinositol 4,5-bisphosphate (PIP2) level in the basal region of hair bundles. Can dephosphorylate a broad range of phosphatidylinositol phosphates, including phosphatidylinositol 3,4,5-trisphosphate and most phosphatidylinositol monophosphates and diphosphates. Phosphate can be hydrolyzed from the D3 and D5 positions in the inositol ring. Has low tyrosine-protein phosphatase activity; however, the relevance of such activity in vivo is unclear. Plays an important role in adipogenesis of mesenchymal stem cells (MSCs). Regulates the phosphorylation state of AKT1 by suppressing the phosphatidylinositol 3,4,5-trisphosphate (PIP3) level in MSCs and preadipocyte cells.

> Gene Ontology
 
Biological Process GO:0006470 protein dephosphorylation
GO:0006644 phospholipid metabolic process
GO:0006650 glycerophospholipid metabolic process
GO:0007423 sensory organ development
GO:0016311 dephosphorylation
GO:0030258 lipid modification
GO:0035335 peptidyl-tyrosine dephosphorylation
GO:0042471 ear morphogenesis
GO:0042472 inner ear morphogenesis
GO:0043583 ear development
GO:0045444 fat cell differentiation
GO:0045598 regulation of fat cell differentiation
GO:0046486 glycerolipid metabolic process
GO:0046488 phosphatidylinositol metabolic process
GO:0046839 phospholipid dephosphorylation
GO:0046856 phosphatidylinositol dephosphorylation
GO:0048562 embryonic organ morphogenesis
GO:0048568 embryonic organ development
GO:0048839 inner ear development
GO:0090596 sensory organ morphogenesis
Molecular Function GO:0004721 phosphoprotein phosphatase activity
GO:0004725 protein tyrosine phosphatase activity
GO:0016791 phosphatase activity
GO:0042578 phosphoric ester hydrolase activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolPTPRQ
Nameprotein tyrosine phosphatase, receptor type, Q
Aliases DFNB84; deafness, autosomal recessive 84; DFNB84A; PTPGMC1; R-PTP-Q; phosphotidylinositol phosphatase PTPRQ; ......
Chromosomal Location12q21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between PTPRQ and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolPTPRQ
Nameprotein tyrosine phosphatase, receptor type, Q
Aliases DFNB84; deafness, autosomal recessive 84; DFNB84A; PTPGMC1; R-PTP-Q; phosphotidylinositol phosphatase PTPRQ; ......
Chromosomal Location12q21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of PTPRQ in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.61 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolPTPRQ
Nameprotein tyrosine phosphatase, receptor type, Q
Aliases DFNB84; deafness, autosomal recessive 84; DFNB84A; PTPGMC1; R-PTP-Q; phosphotidylinositol phosphatase PTPRQ; ......
Chromosomal Location12q21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of PTPRQ in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)141201
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)6501
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)8701
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.1680.797
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.1110.913
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.2540.831
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.130.855
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.0050.441
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.5580.743
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.0580.888
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.0580.926
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.2550.48
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of PTPRQ in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211723.829.4-5.60.727
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8637.516.720.80.58
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131115.436.4-210.357
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38277.922.2-14.30.147
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.115.4-6.30.618
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.228.6-22.40.157
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11139.17.71.41
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 512208.311.70.515
Summary
SymbolPTPRQ
Nameprotein tyrosine phosphatase, receptor type, Q
Aliases DFNB84; deafness, autosomal recessive 84; DFNB84A; PTPGMC1; R-PTP-Q; phosphotidylinositol phosphatase PTPRQ; ......
Chromosomal Location12q21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PTPRQ. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolPTPRQ
Nameprotein tyrosine phosphatase, receptor type, Q
Aliases DFNB84; deafness, autosomal recessive 84; DFNB84A; PTPGMC1; R-PTP-Q; phosphotidylinositol phosphatase PTPRQ; ......
Chromosomal Location12q21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PTPRQ. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PTPRQ.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolPTPRQ
Nameprotein tyrosine phosphatase, receptor type, Q
Aliases DFNB84; deafness, autosomal recessive 84; DFNB84A; PTPGMC1; R-PTP-Q; phosphotidylinositol phosphatase PTPRQ; ......
Chromosomal Location12q21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PTPRQ. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolPTPRQ
Nameprotein tyrosine phosphatase, receptor type, Q
Aliases DFNB84; deafness, autosomal recessive 84; DFNB84A; PTPGMC1; R-PTP-Q; phosphotidylinositol phosphatase PTPRQ; ......
Chromosomal Location12q21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of PTPRQ expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolPTPRQ
Nameprotein tyrosine phosphatase, receptor type, Q
Aliases DFNB84; deafness, autosomal recessive 84; DFNB84A; PTPGMC1; R-PTP-Q; phosphotidylinositol phosphatase PTPRQ; ......
Chromosomal Location12q21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between PTPRQ and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolPTPRQ
Nameprotein tyrosine phosphatase, receptor type, Q
Aliases DFNB84; deafness, autosomal recessive 84; DFNB84A; PTPGMC1; R-PTP-Q; phosphotidylinositol phosphatase PTPRQ; ......
Chromosomal Location12q21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting PTPRQ collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.